Smarter Decisions,
Better Care

UpToDate synthesizes the most recent medical information into evidence-based practical recommendations clinicians trust to make the right point-of-care decisions.

  • Rigorous editorial process: Evidence-based treatment recommendations
  • World-Renowned physician authors: over 5,100 physician authors and editors around the globe
  • Innovative technology: integrates into the workflow; access from EMRs

Choose from the list below to learn more about subscriptions for a:


Subscribers log in here


Related Searches

Motion sickness

INTRODUCTION

Motion sickness is a syndrome that occurs in response to real or perceived motion, which can include gastrointestinal, central nervous system, and autonomic symptoms.

Motion sickness is considered a physiologic form of dizziness, since it is not indicative of a disease process and can be induced in nearly all normal human subjects. There is enormous variability in susceptibility to motion sickness, as it may be produced with minimal provocation in some individuals but can be very difficult to elicit in others.

The symptoms of motion sickness were first described by Hippocrates. They frequently occur during boat travel, and the principal symptom (nausea) is derived from the Greek word for ship (naus).

This topic discusses the pathogenesis, clinical presentation, treatment and prevention of motion sickness. A possibly related disorder, disembarkment syndrome, and other causes of vertigo and dizziness are discussed separately. (See "Pathophysiology, etiology, and differential diagnosis of vertigo".)

PATHOGENESIS

The brain receives numerous inputs that are used to estimate the motion and spatial orientation of the head. The principal sensory signals that contribute to this process are vestibular cues from the labyrinth, visual information, and somatosensory cues. Afferent information derived from the labyrinth encodes both angular motion (sensed by the semicircular canals) and linear acceleration and gravitational force (sensed by the otolith organs).

                       

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Jul 2014. | This topic last updated: Jan 22, 2014.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2014 UpToDate, Inc.
References
Top
  1. Oman CM. Motion sickness: a synthesis and evaluation of the sensory conflict theory. Can J Physiol Pharmacol 1990; 68:294.
  2. Flanagan MB, May JG, Dobie TG. The role of vection, eye movements and postural instability in the etiology of motion sickness. J Vestib Res 2004; 14:335.
  3. Shupak A, Gordon CR. Motion sickness: advances in pathogenesis, prediction, prevention, and treatment. Aviat Space Environ Med 2006; 77:1213.
  4. Miller EF 2nd, Graybiel A. Semicircular canals as a primary etiological factor in motion sickness. Aerosp Med 1972; 43:1065.
  5. Brizzee KR, Igarashi M. Effect of macular ablation on frequency and latency of motion-induced emesis in the squirrel monkey. Aviat Space Environ Med 1986; 57:1066.
  6. James W. The sense of dizziness in deaf-mutes. Am J Otol 1882; 4:239.
  7. Graybiel A. Susceptibility to acute motion sickness in blind persons. Aerosp Med 1970; 41:650.
  8. Woodman PD, Griffin MJ. Effect of direction of head movement on motion sickness caused by Coriolis stimulation. Aviat Space Environ Med 1997; 68:93.
  9. Balaban CD, Porter JD. Neuroanatomic substrates for vestibulo-autonomic interactions. J Vestib Res 1998; 8:7.
  10. Dai M, Kunin M, Raphan T, Cohen B. The relation of motion sickness to the spatial-temporal properties of velocity storage. Exp Brain Res 2003; 151:173.
  11. Cohen B, Dai M, Raphan T. The critical role of velocity storage in production of motion sickness. Ann N Y Acad Sci 2003; 1004:359.
  12. Takeda N, Morita M, Hasegawa S, et al. Neuropharmacology of motion sickness and emesis. A review. Acta Otolaryngol Suppl 1993; 501:10.
  13. Cohen B, Dai M, Yakushin SB, Raphan T. Baclofen, motion sickness susceptibility and the neural basis for velocity storage. Prog Brain Res 2008; 171:543.
  14. Cooper C, Dunbar N, Mira M. Sex and seasickness on the Coral Sea. Lancet 1997; 350:892.
  15. Gahlinger PM. Motion sickness. How to help your patients avoid travel travail. Postgrad Med 1999; 106:177.
  16. Grunfeld E, Gresty MA. Relationship between motion sickness, migraine and menstruation in crew members of a "round the world" yacht race. Brain Res Bull 1998; 47:433.
  17. Barabas G, Matthews WS, Ferrari M. Childhood migraine and motion sickness. Pediatrics 1983; 72:188.
  18. Kayan A, Hood JD. Neuro-otological manifestations of migraine. Brain 1984; 107 ( Pt 4):1123.
  19. Drummond PD. Triggers of motion sickness in migraine sufferers. Headache 2005; 45:653.
  20. Marcus DA, Furman JM, Balaban CD. Motion sickness in migraine sufferers. Expert Opin Pharmacother 2005; 6:2691.
  21. Drummond PD, Granston A. Facial pain increases nausea and headache during motion sickness in migraine sufferers. Brain 2004; 127:526.
  22. Drummond PD. Effect of tryptophan depletion on symptoms of motion sickness in migraineurs. Neurology 2005; 65:620.
  23. Marcus DA, Furman JM. Prevention of motion sickness with rizatriptan: a double-blind, placebo-controlled pilot study. Med Sci Monit 2006; 12:PI1.
  24. Murray JB. Psychophysiological aspects of motion sickness. Percept Mot Skills 1997; 85:1163.
  25. Eden D, Zuk Y. Seasickness as a self-fulfilling prophecy: raising self-efficacy to boost performance at sea. J Appl Psychol 1995; 80:628.
  26. Turner M, Griffin MJ, Holland I. Airsickness and aircraft motion during short-haul flights. Aviat Space Environ Med 2000; 71:1181.
  27. Gahlinger PM. Cabin location and the likelihood of motion sickness in cruise ship passengers. J Travel Med 2000; 7:120.
  28. Lawther A, Griffin MJ. A survey of the occurrence of motion sickness amongst passengers at sea. Aviat Space Environ Med 1988; 59:399.
  29. Lindseth G, Lindseth PD. The relationship of diet to airsickness. Aviat Space Environ Med 1995; 66:537.
  30. Hu S, Lagomarsino JJ, Luo YJ. Drinking milk or water has no effect on the severity of optokinetic rotation-induced symptoms of motion sickness. Aviat Space Environ Med 1998; 69:1158.
  31. Money KE. Motion sickness. Physiol Rev 1970; 50:1.
  32. Spinks AB, Wasiak J, Villanueva EV, Bernath V. Scopolamine (hyoscine) for preventing and treating motion sickness. Cochrane Database Syst Rev 2007; :CD002851.
  33. Ungs TJ. Simulator induced syndrome in Coast Guard aviators. Aviat Space Environ Med 1988; 59:267.
  34. Murdin L, Golding J, Bronstein A. Managing motion sickness. BMJ 2011; 343:d7430.
  35. Brandt T, Dichgans J, Wagner W. Drug effectiveness on experimental optokinetic and vestibular motion sickness. Aerosp Med 1974; 45:1291.
  36. Buckey JC, Alvarenga D, Cole B, Rigas JR. Chlorpheniramine for motion sickness. J Vestib Res 2004; 14:53.
  37. Lucertini M, Mirante N, Casagrande M, et al. The effect of cinnarizine and cocculus indicus on simulator sickness. Physiol Behav 2007; 91:180.
  38. Weinstein SE, Stern RM. Comparison of marezine and dramamine in preventing symptoms of motion sickness. Aviat Space Environ Med 1997; 68:890.
  39. Kohl RL, Homick JL, Cintron N, Calkins DS. Lack of effects of astemizole on vestibular ocular reflex, motion sickness, and cognitive performance in man. Aviat Space Environ Med 1987; 58:1171.
  40. Cheung BS, Heskin R, Hofer KD. Failure of cetirizine and fexofenadine to prevent motion sickness. Ann Pharmacother 2003; 37:173.
  41. Dornhoffer J, Chelonis JJ, Blake D. Stimulation of the semicircular canals via the rotary chair as a means to test pharmacologic countermeasures for space motion sickness. Otol Neurotol 2004; 25:740.
  42. Gil A, Nachum Z, Tal D, Shupak A. A comparison of cinnarizine and transdermal scopolamine for the prevention of seasickness in naval crew: a double-blind, randomized, crossover study. Clin Neuropharmacol 2012; 35:37.
  43. Estrada A, LeDuc PA, Curry IP, et al. Airsickness prevention in helicopter passengers. Aviat Space Environ Med 2007; 78:408.
  44. Gil A, Nachum Z, Dachir S, et al. Scopolamine patch to prevent seasickness: clinical response vs. plasma concentration in sailors. Aviat Space Environ Med 2005; 76:766.
  45. Davis JR, Jennings RT, Beck BG, Bagian JP. Treatment efficacy of intramuscular promethazine for space motion sickness. Aviat Space Environ Med 1993; 64:230.
  46. Kohl RL. Failure of metoclopramide to control emesis or nausea due to stressful angular or linear acceleration. Aviat Space Environ Med 1987; 58:125.
  47. Wood CD, Stewart JJ, Wood MJ, et al. Therapeutic effects of antimotion sickness medications on the secondary symptoms of motion sickness. Aviat Space Environ Med 1990; 61:157.
  48. McClure JA, Lycett P, Baskerville JC. Diazepam as an anti-motion sickness drug. J Otolaryngol 1982; 11:253.
  49. Benline TA, French J, Poole E. Anti-emetic drug effects on pilot performance: granisetron vs. ondansetron. Aviat Space Environ Med 1997; 68:998.
  50. Muth ER, Elkins AN. High dose ondansetron for reducing motion sickness in highly susceptible subjects. Aviat Space Environ Med 2007; 78:686.
  51. Hershkovitz D, Asna N, Shupak A, et al. Ondansetron for the prevention of seasickness in susceptible sailors: an evaluation at sea. Aviat Space Environ Med 2009; 80:643.
  52. Nicholson AN, Stone BM, Turner C, Mills SL. Central effects of cinnarizine: restricted use in aircrew. Aviat Space Environ Med 2002; 73:570.
  53. Cowings PS, Toscano WB, DeRoshia C, Miller NE. Promethazine as a motion sickness treatment: impact on human performance and mood states. Aviat Space Environ Med 2000; 71:1013.
  54. Gordon CR, Gonen A, Nachum Z, et al. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance. J Psychopharmacol 2001; 15:167.
  55. Paule MG, Chelonis JJ, Blake DJ, Dornhoffer JL. Effects of drug countermeasures for space motion sickness on working memory in humans. Neurotoxicol Teratol 2004; 26:825.
  56. Paul MA, MacLellan M, Gray G. Motion-sickness medications for aircrew: impact on psychomotor performance. Aviat Space Environ Med 2005; 76:560.
  57. Buckey JC Jr, Alvarenga DL, MacKenzie TA. Chlorpheniramine and ephedrine in combination for motion sickness. J Vestib Res 2007; 17:301.
  58. Palatty PL, Haniadka R, Valder B, et al. Ginger in the prevention of nausea and vomiting: a review. Crit Rev Food Sci Nutr 2013; 53:659.
  59. Grøntved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness. A controlled trial on the open sea. Acta Otolaryngol 1988; 105:45.
  60. Lien HC, Sun WM, Chen YH, et al. Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection. Am J Physiol Gastrointest Liver Physiol 2003; 284:G481.
  61. Holtmann S, Clarke AH, Scherer H, Höhn M. The anti-motion sickness mechanism of ginger. A comparative study with placebo and dimenhydrinate. Acta Otolaryngol 1989; 108:168.
  62. Ghayur MN, Gilani AH. Pharmacological basis for the medicinal use of ginger in gastrointestinal disorders. Dig Dis Sci 2005; 50:1889.
  63. Abdel-Aziz H, Windeck T, Ploch M, Verspohl EJ. Mode of action of gingerols and shogaols on 5-HT3 receptors: binding studies, cation uptake by the receptor channel and contraction of isolated guinea-pig ileum. Eur J Pharmacol 2006; 530:136.
  64. Hu S, Stritzel R, Chandler A, Stern RM. P6 acupressure reduces symptoms of vection-induced motion sickness. Aviat Space Environ Med 1995; 66:631.
  65. Stern RM, Jokerst MD, Muth ER, Hollis C. Acupressure relieves the symptoms of motion sickness and reduces abnormal gastric activity. Altern Ther Health Med 2001; 7:91.
  66. Bertalanffy P, Hoerauf K, Fleischhackl R, et al. Korean hand acupressure for motion sickness in prehospital trauma care: a prospective, randomized, double-blinded trial in a geriatric population. Anesth Analg 2004; 98:220.
  67. Bruce DG, Golding JF, Hockenhull N, Pethybridge RJ. Acupressure and motion sickness. Aviat Space Environ Med 1990; 61:361.
  68. Warwick-Evans LA, Masters IJ, Redstone SB. A double-blind placebo controlled evaluation of acupressure in the treatment of motion sickness. Aviat Space Environ Med 1991; 62:776.
  69. Miller KE, Muth ER. Efficacy of acupressure and acustimulation bands for the prevention of motion sickness. Aviat Space Environ Med 2004; 75:227.
  70. Golding JF, Prosyanikova O, Flynn M, Gresty MA. The effect of smoking nicotine tobacco versus smoking deprivation on motion sickness. Auton Neurosci 2011; 160:53.